Amgen Inc.
Recent
price
P/E
ratio
div
yld
2.17%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures and delivers innovative human therapeutics worldwide, focusing on biotechnology to treat serious illnesses in oncology, inflammation, cardiovascular disease, bone health, nephrology, neuroscience and rare diseases. Headquartered in Thousand Oaks, California, the company was founded in 1980 as Applied Molecular Genetics and pioneered the biotechnology industry with recombinant DNA technology. Amgen operates globally with manufacturing facilities in the United States, Ireland, Puerto Rico, Singapore, the Netherlands and other locations, serving patients through wholesalers and healthcare providers. The company's principal products include Prolia and Xgeva (denosumab) for osteoporosis and bone diseases; Enbrel (etanercept) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis and plaque psoriasis; Repatha (evolocumab) for hyperlipidemia; Otezla (apremilast) for psoriasis and psoriatic arthritis; Tepezza (teprotumumab) for Graves' ophthalmopathy; Evenity (romosozumab) for osteoporosis; Kyprolis (carfilzomib) for multiple myeloma; Nplate (romiplostim) for thrombocytopenia; Aranesp (darbepoetin alfa) for anemia; Neulasta (pegfilgrastim) and Neupogen (filgrastim) for neutropenia; Epogen (epoetin alfa) for anemia; Aimovig (erenumab) for migraine; Blincyto (blinatumomab) for acute lymphoblastic leukemia; Lumakras (sotorasib) for KRAS G12C-mutated non-small cell lung cancer; Tezspire (tezepelumab) for severe asthma; Vectibix (panitumumab) for colorectal cancer; Parsabiv (etelcalcetide) for secondary hyperparathyroidism; biosimilars such as Amjevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), Riabni (rituximab) and Avsola (infliximab); and rare disease therapies including Krystexxa (pegloticase), Uplizna (inebilizumab) and Tavneos (avacopan). Amgen maintains a robust pipeline with 17 Phase III programs, including MariTide (maridebart cafraglutide), an investigational once-monthly anti-obesity therapy; Imdelltra (tarlatamab), a bispecific T-cell engager for extensive-stage small cell lung cancer; and advancements in oncology, cardiovascular and rare disease areas. Recent developments include major manufacturing expansions with a $650 million investment at its Juncos, Puerto Rico facility announced in September 2025 to enhance biologics production and create nearly 750 jobs; a $900 million expansion at its New Albany, Ohio biomanufacturing plant in April 2025; a $600 million Center for Science and Innovation at its Thousand Oaks headquarters broken ground in October 2025; and a $1 billion project at its Holly Springs, North Carolina site. In August 2025, Royalty Pharma acquired a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront. The company strengthened its portfolio through acquisitions including Horizon Therapeutics for $27.8 billion in 2023 adding Tepezza, Krystexxa and Uplizna; ChemoCentryx for $3.7 billion in 2022 adding Tavneos; and others such as Otezla from Celgene in 2019. Amgen continues collaborations like those with Kyowa Kirin, AstraZeneca and Generate Biomedicines, while advancing AI partnerships with Amazon Web Services for drug discovery announced in 2023.
Company News
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Here's Why Amgen (AMGN) Fell More Than Broader Market
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different
Amgen (AMGN) Gains As Market Dips: What You Should Know
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
Here's Why Amgen (AMGN) is a Strong Growth Stock
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
2,560 Amgen Inc. $AMGN Shares Sold by Generali Investments Management Co LLC